OverviewChartNewsTraderScreen

BNP Paribas Knock-Out 4AB/  DE000PD31LU7  /

Frankfurt Zert./BNP
7/4/2024  9:50:39 PM Chg.-0.110 Bid7/4/2024 Ask7/4/2024 Underlying Strike price Expiration date Option type
2.540EUR -4.15% 2.540
Bid Size: 6,500		 -
Ask Size: -		 ABBVIE INC. D... 192.4684 - 12/31/2078 Put
GlobeNewswire 7/1 Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
GlobeNewswire 7/1 OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in A...
GlobeNewswire 6/28 NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
GlobeNewswire 6/28 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire 6/28 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire 6/27 Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Ach...
GlobeNewswire 6/26 COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors
GlobeNewswire 6/25 CEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel’s $45 Per Share Deal is Being Investigated by BFA Law, Sh...
GlobeNewswire 6/24 OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell...
GlobeNewswire 6/22 CEREVEL (NASDAQ:CERE) INVESTOR ALERT: Cerevel’s $45 Per Share Offer is Being Investigated by BFA Law...
GlobeNewswire 6/21 Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest C...
GlobeNewswire 6/20 CEREVEL INVESTOR REMINDER: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law...
GlobeNewswire 6/20 OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of I...
GlobeNewswire 6/19 OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the B...
GlobeNewswire 6/19 Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewswire 6/18 CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...
GlobeNewswire 6/18 CEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoi...
GlobeNewswire 6/17 CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
GlobeNewswire 6/17 Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, B...
GlobeNewswire 6/15 CEREVEL STOCK NOTICE: Think $45 Per Share is Too Low for Cerevel (Nasdaq: CERE)? Contact BFA Law abo...
Newsfile Corp 6/13 BioMed X Launches New US Institute in New Haven, CT
GlobeNewswire 6/13 Anima Biotech to Present at the Society for Medicines Research’s Modulating RNA with Oligonucleotide...
GlobeNewswire 6/13 LifeSci Advisors Announces Appointment of Chris Howerton Ph.D.
GlobeNewswire 6/13 CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investi...
GlobeNewswire 6/13 What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...